Category Archives: Stem Cell Research

Experts discuss stem cell banking ethics, policies By Noimot OlayiwolaStaff Reporter Umbilical cord blood banking and transplantation, issues of ethics and policy as well as regulations governing stem cell banking were some of the high points of discussion during a session on â??Stem Cell Bankingâ?? at the Qatar International Conference on Stem Cells Science and Policy, underway at the Qatar National Convention Centre. Sharing the Saudi Arabia experience on umbilical cord blood transplantation during a presentation, King Faisal Specialist Hospital and Research Centreâ??s blood bank (transfusion & donor services) director and of the Stem Cell Cord Blood Bank at the department of pathology and laboratory medicine, Dr Hind al-Humaidan, noted that the transplantation of allogeneic (taken from different individuals of the same species) bone marrow has been successfully used in the treatment of high risk or recurrent hematologic malignancies, bone marrow failure syndromes, selected hereditary immunodeficiency states and metabolic disorders. â??Early in the history of bone marrow transplantation, it was clear that access to a suitable donor was a major obstacle severely limiting the use of this potentially curative treatment modality. Although using an HLA (human leukocyte antigen) sibling donor is the best choice for transplantation, not all patients could have access to such a donor. Therefore transplant centres explored the possibility of using volunteer adult unrelated donors as an alternative to HLAâ??matched siblings,â? she noted while mentioning that there was another alternative treatment strategy as a source of hematopoietic stem cell namely umbilical cord blood. She explained that in Saudi Arabia, 60% of patients who need a transplant will find an HLA-matched sibling donor, leaving 40% of the patients in need of alternative sources. The figure of donor with HLA-matched sibling elsewhere in the world is 45%, she said. â??The concept of establishing a cord blood bank in Saudi Arabia, under the umbrella of King Faisal Specialist Hospital and Research Centre, was raised after an increase in use of cord blood for transplantation due to the inability of finding fully or closely HLA-matched related donors. This non-profit public Cord Blood Bank is dedicated to making high quality cord blood units available to all patients in need of related and/or unrelated transplantation in Saudi Arabia and in the neighbouring countries through the development and maintenance of a centre of excellence for the collection, storage, search and distribution of ethnically and racially diverse cord blood units,â? she said. According to al-Humaidan, till date, the Cord Blood inventory consists of 3,725 units of high quality cord blood with a total of 70 cord blood transplants being carried out from the inventory. Virgin Health Bank (VHB) chief executive officer Dr Rajan Jethwa discussed ways to make a cord blood bank attractive to users and how to ensure sustenance, especially when government funding of such facilities stops. He described how VHB will become the magnet that will pull all stakeholders in the field of stem cell banking including researchers, technicians together towards achieving the establishment of a stem cell bank in Qatar. Wake Forest School of Medicineâ??s Internal Medicine and Institute for Regenative Medicine Social Sciences and Health Policy professor Nancy King highlighted some of the ethical and policy issues governing stem cell banking globally while Field Fisher Waterhouseâ??s Public and Regulatory Law Group head Sarah Ellson shared some tips on ensuring regulations of biosamples. University of Central Lancashireâ??s Dr Katrina Aisha Choog spoke on informed consent among Arab Muslim research participants. The session was chaired by Harvard Stem Cell Instituteâ??s executive director Brock Reeve.

See the rest here:
Experts discuss stem cell banking ethics, policies

Diverse approach to cancer research need of the hour, stresses professor Profoundly different approaches are needed for cancer research, the Qatar International Conference on Stem Cell Science and Policy 2012, has been told by an expert in cancer stem cell (CSC) biology. Professor Irving Weissman, director, Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, was delivering a keynote address on â??Normal and neoplastic stem cellsâ?? yesterday. â??Self-renewal is the principal property that distinguishes stem cells from their daughter cells,â? he said while explaining that when stem cells divide they give rise to stem cells (by self-renewal) and progenitors (by differentiation). The balance between self-renewal and differentiation is what generates, and then maintains, tissues enabling them to respond to injury or other stressors. Studies identifying hematopoietic stem cells (HSC) - which form blood and immune cells - and progenitors, have made hematopoiesis one of the best systems for studying the molecular changes in cell fate decision-making and creation of cancer. Further, it serves as a paradigm for finding preclinical and clinical platforms for tissue and organ replacement and regeneration. Stem cell isolation and transplantation is the basis for regenerative medicine. Self-renewal is dangerous and therefore strictly regulated. Poorly regulated self-renewal can lead to the genesis of CSC â?? the only cells within a tumour or leukaemia that have the ability to self renew, and therefore the cells that maintain the cancer. â??Thus, it is predicted that CSC elimination is required for cure. This prediction necessitates profoundly different approaches to cancer research, compelling investigators to prospectively isolate CSCs and to characterise the molecular pathways regulating their behaviour in order to identify targeted and truly effective therapies,â? Weissman added. A founder of three companies â?? SyStemix, Cellerant, and Stem Cells Inc â?? all focused on bringing stem cell therapies into the clinic, Weissman has authored more than 700 scientific articles and has been an editor of multiple scientific journals.

Read more here:
Diverse approach to cancer research need of the hour, stresses professor

A long-held belief about women and fertility is that each woman has a set amount of eggs in her lifetime and that when those eggs are depleted at menopause, so are her chances at having a biological child. However, research out of Massachusetts General Hospital is questioning that view. Using stem cells taken from human ovaries, scientists have produced early-stage eggs, which brings up all sorts of questions about possible new methods for treating infertility. Nicholas Wade, writing in The New York Times, adds, "The ability to isolate stem cells from which eggs could be cultivated would help not only with fertility but also with biologists' understanding of how drugs and nutrition affect the egg cells."
Jonathan Tilly, the director of Mass General's Vincent Center for Reproductive Biology and leader of the new research, had reported in 2004 that ovarian stem cells in mice could create new eggs "similar to how stem cells in male testes produce sperm throughout a man's life." His new study attempted to prove this with humans. Researchers took healthy ovaries from patients having sex reassignment surgery, and injected stem cells from the ovaries into human ovarian tissue grafted under the skin of mice: "Within two weeks, early stage human follicles with oocytes had formed." Ryan Flinn writes in Bloomberg Businessweek that this could potentially point at "new ways to aid fertility by delaying when the ovaries stop functioning."
Read the full story at The Atlantic Wire.

The rest is here:
Stem Cell Research Could Allow Women Post-Menopause Babies

SAN DIEGO, CA and PORTLAND, OR--(Marketwire -02/28/12)- Medistem Inc. (Pinksheets: MEDS.PK - News) announced today its Annual "Evening with Medistem" Event will take place in Portland, Oregon on March 7th, 2012. The event is being hosted by Vladimir Zaharchook, Vice Chairman at Medistem, Inc., and will feature stem cell luminaries and pioneers working with Medistem including Dr. Amit Patel, Director of Regenerative Medicine at University of Utah and the first person to administer stem cells into patients with heart failure, Dr. Michael Murphy, Vascular Surgeon at Indiana University and Principal Investigator for Medistem's FDA clinical trial in patients with risk of amputation, and Dr. Alan Lewis, former CEO of the Juvenile Diabetes Research Foundation, advisory board member of Medistem.
In 2007 Medistem discovered an entirely new type of stem cell, the Endometrial Regenerative Cell (ERC). This cell has proven it is a "universal donor" and can be used to treat many more conditions compared to other types of stem cells. The company received FDA clearance to begin clinical trials in September of 2011 for critical limb ischemia, a condition that is associated with amputation. Medistem is also running a Phase II clinical trial for heart failure using the new stem cell. The ERC stem cell does not involve the highly controversial use of fetal tissue, can be produced very economically and administered to the patient in a very simple manner. Medistem is exploring ways to expand clinical trials of its stem cell into other diseases.
"Stem cells and regenerative medicine offer hope in clinical conditions in which hope previously did not exist," said Dr. Stanley Cohan, Head of Neurology at the St Vincent's Hospital, the largest center for treatment of multiple sclerosis in the Pacific Northwest, who will be attending the event. "We are honored in the Portland community to have this distinguished team of accomplished researchers and medical doctors convene here and discuss with us possible collaborations."
"As a long-time member of the Portland academic community, it is exciting to have companies such as Medistem to visit us and share their experiences 'from the trenches' of what it takes to push a cellular drug through the FDA," said Dr. Shoukrat Milipotiv, Associate Scientist in the Division of Reproductive & Developmental Sciences of ONPRC, Oregon Stem Cell Center and Departments of Obstetrics & Gynecology and Molecular & Medical Genetics, and co-director of the ART/ESC core at the Center. He is an internationally recognized researcher in the area of stem cells.
"The Event is an annual celebration to honor our team and collaborators for the successes of the previous year, while at the same time educate the local business and medical community on the latest research on stem cells not just at Medistem but internationally," said Thomas Ichim, Ph.D Chief Executive Officer of Medistem Inc. "2012 is particularly exciting for us due to approvals for two clinical trials, and the initiation of patient treatments within this context."
About Medistem Inc.
Medistem Inc. is a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company's lead product, the endometrial regenerative cell (ERC), is a "universal donor" stem cell being developed for critical limb ischemia and heart failure.
Cautionary Statement
This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.

Read the original here:
Stem Cell Pioneers Converge in Portland to Discuss and Celebrate a Revolutionary New Stem Cell Entering Human Clinical ...

SALT LAKE CITY — Researchers may have found a use for the chemical that causes the stench in bad breath, stink bombs, and flatulence.

This smelly substance known as Hydrogen Sulphide has been used in helping to convert stem cells from human teeth into liver cells.

The scientists conducting the investigation and research in the Journal of Breath Research claim that the gas increased the purity of the stem cells. The goal is that the liver cells produced from the stem cells could be used for repair if the organ was damaged.

Hydrogen Sulphide is produced by bacteria, and is toxic in large amounts. A group in China has reportedly tested the gas on rats to enhance the survival of mesenchymal stem cells taken from the bone marrow.

Researchers from the Nippon Dental University were investigating stem cells from dental pulp — the material in the middle of the tooth. The dental pulp was taken from patients undergoing a routine tooth extraction.

Dr. Ken Yaegaki, the lead author of the study, told the BBC why the dental pulp was so effective. "High purity means there are less 'wrong cells' that are being differentiated to other tissues, or remaining as stem cells," said Yaegaki.

However, one of the concerns with dental pulp as a source of stem cells is the limited number that can be harvested. The study did not say how many stem cells were actually produced.

But researchers are optimistic about the results, and the safety of the procedure.

"Until now, nobody has produced the protocol to regenerate such a huge number of hepatic cells for human transplantation," said Yaegaki. "Compared to the traditional method of using fetal bovine serum to produce the cells, our method is productive and, most importantly, safe."

View post:
Bad breath being used in Stem Cell research

By Noimot Olayiwola
Staff Reporter
Researchers and scientists in the field of both embryonic and adult stem cells research in the Middle East were yesterday urged to be more open to collaboration and networking among themselves in order to build on their already acquired and existing strengths for the betterment of the future use of stem cells in curing genetic diseases in the region.
Stem cells are ‘unspecialised’ cells that are able to divide and produce copies of themselves and having the potential to differentiate, that is, to produce other cell types in the body.
Speaking on how to further expand the scope of stem cell research in the region during a panel discussion yesterday at the ongoing Qatar International Conference on Stem Cell Science and Policy, Weill Cornell Medical College in Qatar’s Dr Jeremie Arash Rafii Tabrizi said there was the need for the region’s researchers in the field of stem cells to know each other and come together to network and form collaborations.
“I believe that each and everyone in the field within this region has built some sort of strength while conducting their individual researches, so I will suggest that we all come together to put heads together and also explore how we can benefit from our colleagues elsewhere. And if we can be more diseases-focused in our researches, I believe it is a good way to move forward,” he noted.
Making a presentation on “Stem Cell Research: From Promise to Practice”, Dr Aida al-Aqeel, of Riyadh Military Hospital’s paediatrics department, maintained that it would take a while before stem cell research can become a ‘clinical reality’.
“Despite that stem cell research is at the forefront of the need for research to cure most degenerative diseases, it will still take a long way for the stem cell research to become achievable clinically because the embryonic stem cells (ESCs) have huge therapeutic potential as they can give rise to every cell type in the body (pluripotency) as compared to adult stem cells (ASCs) from certain adult tissues that can only differentiate into a limited range of cell types,” she said.
“However, this research raises sensitive ethical and religious arguments, which are balanced against possible great benefit of such research for the patients suffering from so far incurable diseases. Serious questions remain about safety,” she said, noting that the ability for stem cells to be expanded in culture without genetic and epigenetic abnormalities and their ability to form functional cell types in vitro and in vivo, and their immuno-compatibility with the patient still need to be studied.
“In Saudi Arabia, for the last five years, the Stem Cell Therapy Programme has been established at King Faisal Specialist Hospital and Research Centre with the launch of 10 projects. Embryonic stem cell therapy for genetics metabolic disorders is one of the most promising modalities for the therapy and prevention of mentally and physically handicapped in children,” she said while sharing experiences from the KSA.
She pointed out how Islamic teachings make embryonic stem cell research and therapeutic technique, and its modality of treatment permissible as well as the Islamic perspectives about reproductive/therapeutic cloning.
“The focus of research community should be on developing human research capacity in both ASCs and ESCs. Each type of research will take time to mature. The ethical debate will need to produce acceptable policy and regulatory compromises so that the regulatory burden can be reduced and investors’ risk aversion can be overcome,” she stated.
Other speaker during the session moderated by WCMC-Q dean Dr Javaid Sheikh were Professor Hossein Baharvand from the Royan Institute for Reproductive Biomedicine Stem Cell Biology and Technology on “A Chemical Approach to Efficient Generating Embryonic and Germline-derived Pluripotent Stem Cells”.

Read more from the original source:
Scientists urged to share data on stem cells research

Harvard scientists are challenging traditional medical logic that dictates that women are born with a finite amount of eggs.  The scientists said they have discovered the ovaries of young women harbor rare stem cells that are in fact capable of producing new eggs.

If properly harnessed, those stem cells may someday lead to new treatments for women suffering from infertility due to cancer or other diseases – or for those who are simply getting older, according to the researchers.  Lead researcher Jonathan Tilly of Harvard's Massachusetts General Hospital has co-founded a company, OvaScience Inc., to try to develop the findings into fertility treatments.

The idea that women are born with all the egg cells – called oocytes – they’ll ever have has been called into question by past research, which found egg-producing stem cells in adult mice.

In this latest study, Harvard researchers, in collaboration with Japanese scientists, used donated frozen ovaries from 20 year olds and ‘fished out’ the purported stem cells.  

The researchers inserted a gene into the stem cells, which caused them to glow green.  If the cells produced eggs, those would glow green, too.

The researchers first watched through a microscope as new eggs grew in a lab dish.  They then implanted the human tissue under the skin of mice to provide a nourishing blood supply.  Within two weeks, they observed green-tinged cells forming.

While the work of the Harvard scientists does show potential, there are still questions as to whether the cells are capable of growing into mature, usable eggs.

If so, researchers said, it might be possible one day to use the stem cells in order to grow eggs in lab dishes to help preserve cancer patients’ fertility, which can be harmed by chemotherapy.

Now, I just want to say, while this would be a remarkable discovery – if it pans out – I do have a few concerns. 

I think for specific patients in prime, childbearing ages, who are at risk of losing their fertility for one reason or another, this could be a fruitful discovery for them.

Be that as it may, I am totally against commercializing this technology to the point where women going through menopause look at this as another way of getting pregnant.  For many, this could create incredibly high-risk pregnancies, among other medical problems.

While science is capable of great discovery and innovation – particularly in the field of stem cells – I believe that with reproductive medicine, we should move forward with great caution to minimize any risk to mother and baby.

See more here:
Stem cell fertility treatments could be risky for older women

NEW YORK & PETACH TIKVAH--(BUSINESS WIRE)--

BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI.OB - News), a leading developer of adult stem cell technologies and therapeutics, announced today that the prestigious Nature Reviews Neurology, a Nature Publishing Group Journal, highlighted recently published preclinical research results indicating that stem cells, generated with Brainstorm’s NurOwn™ technology, provide hope for Huntington disease's patients.

In the preclinical studies conducted by leading scientists including Professors Melamed and Offen of Tel Aviv University and originally reported in Experimental Neurology, patients' bone marrow derived mesenchymal stem cells secreting neurotrophic factors (MSC-NTF) that were transplanted into an animal model of Huntington disease showed therapeutic benefits.

Addressing the role of these MSC-NTF cells in Huntington disease, Professor Daniel Offen explains, "the premise is that such cells can be transplanted safely into affected areas of the brain, and thereby serve as vehicles for delivering neurotrophic factors." Offen expressed his hope that this cell-based therapy may eventually progress to the clinic.

BrainStorm is currently conducting a Phase I/II Human Clinical Trial for Amyotrophic Lateral Sclerosis (ALS) also known as Lou Gehrig’s disease at the Hadassah Medical center. Initial results have shown that Brainstorm’s NurOwn™ therapy is safe, does not show any significant treatment-related adverse events, and have also shown certain signs of beneficial clinical effects.

Follow this link for the Research Highlights page in Nature Reviews Neurology (starts Feb. 28th ): http://www.nature.com/nrneurol/journal/vaop/ncurrent/index.html

To read the Original Article entitled ‘Mesenchymal stem cells induced to secrete neurotrophic factors attenuate quinolinic acid toxicity: A potential therapy for Huntington's disease’ by Sadan et al. follow this link: http://www.sciencedirect.com/science/article/pii/S0014488612000295

About BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is a biotech company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of neurodegenerative diseases. The company, through its wholly owned subsidiary Brainstorm Cell Therapeutics Ltd., holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot (www.ramot.org) at Tel Aviv University Ltd., the technology transfer company of Tel-Aviv University. The technology is currently in a Phase I/II clinical trials for ALS in Israel.

Safe Harbor Statement

Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements, including, inter alia, regarding safety and efficacy in its human clinical trials and thereafter; the Company's ability to progress any product candidates in pre-clinical or clinical trials; the scope, rate and progress of its pre-clinical trials and other research and development activities; the scope, rate and progress of clinical trials we commence; clinical trial results; safety and efficacy of the product even if the data from pre-clinical or clinical trials is positive; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of our proposed product candidates; dependence on the efforts of third parties; failure by us to secure and maintain relationships with collaborators; dependence on intellectual property; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility, and risks that we may lack the financial resources and access to capital to fund our operations. The potential risks and uncertainties include risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect its technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. The Company does not undertake any obligation to update forward-looking statements made by us.

Go here to read the rest:
Nature: BrainStorm's NurOwn™ Stem Cell Technology Offers Hope for Treating Huntington Disease

NEWARK, Calif., Feb. 27, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM - News) today announced that it will participate in the Qatar International Conference on Stem Cell Science and Policy, which is being held in Qatar from February 27 to March 1, 2012. The Company, which is the leader in development of cell-based therapeutics for central nervous system disorders, was specifically invited by the conference's sponsors, the State of Qatar and Amir of Qatar His Highness Sheikh Hamad bin Khalifa Al-Thani, as well as the James A. Baker III Institute for Public Policy of Rice University, and is the only company to be invited.

Ann Tsukamoto, Ph.D., StemCells' Executive Vice President, Research and Development, will make a presentation on the clinical translation of human neural stem cells. StemCells was the first company to receive authorization from the US Food and Drug Administration to conduct a clinical trial of purified human neural stem cells, and the Company is currently conducting two clinical trials with a third anticipated to start later this year. Dr. Tsukamoto will also be the moderator of the panel session on neurological disorders, which is scheduled to be held on March 1 from 9:30 a.m. to 11:00 a.m. Arabian Standard Time (AST).

In addition, Irving Weissman, M.D., Chairman of StemCells' Scientific Advisory Board, will make a keynote presentation to the conference on Tuesday, February 28 at 9:00 a.m. AST. Dr. Weissman, who is Virginia and Daniel K. Ludwig Professor of Cancer Research, Professor of Pathology and Professor of Developmental Biology at the Stanford School of Medicine, and Director of the Stanford Institute of Stem Cell Biology and Regenerative Medicine, will speak on normal and neoplastic stem cells. Dr. Weissman will also participate in a panel discussion on the opportunities and challenges for stem cell research, and will moderate a panel discussion on pluripotent stem cells.

The Qatar International Conference on Stem Cell Science and Policy will bring together more than 400 international participants from industry, academia and public policy, including leading experts from each of these sectors. The conference's objectives are to showcase the latest stem cell research from around the world, while promoting discussion and awareness of scientific, ethical and regulatory issues related to this innovative and dynamic field.

About StemCells, Inc.

StemCells, Inc. is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company's lead therapeutic product candidate, HuCNS-SC(R) cells (purified human neural stem cells), is currently in development as a potential treatment for a broad range of central nervous system disorders. The Company recently completed a clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children, and expects to report the trial results soon. The Company is also conducting a Phase I/II clinical trial in chronic spinal cord injury, and expects to initiate a Phase I/II clinical trial in dry age- related macular degeneration in the near future. In addition, the Company is pursuing preclinical studies of its HuCNS-SC cells in Alzheimer's disease. StemCells also markets stem cell research products, including media and reagents, under the SC Proven(R) brand, and is developing stem cell-based assay platforms for use in pharmaceutical research, drug discovery and drug development. Further information about StemCells is available at http://www.stemcellsinc.com.

The StemCells, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7014

Apart from statements of historical fact, the text of this press release constitutes forward-looking statements within the meaning of the U.S. securities laws, and is subject to the safe harbors created therein. These statements include, but are not limited to, statements regarding the clinical development of its HuCNS-SC cells; the Company's ability to commercialize drug discovery and drug development tools; and the future business operations of the Company. These forward-looking statements speak only as of the date of this news release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management's current views and are based on certain assumptions that may or may not ultimately prove valid. The Company's actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including those described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2010 and in its subsequent reports on Form 10-Q and Form 8-K.

Visit link:
StemCells, Inc. to Participate in Qatar International Conference on Stem Cell Science and Policy 2012

A long-held belief about women and fertility is that each woman has a set amount of eggs in her lifetime and that when those eggs are depleted at menopause, so are her chances at having a biological child. However, research out of Massachusetts General Hospital questioning that view. Using stem cells taken from human ovaries, scientists have produced early-stage eggs, which brings up all sorts of questions about possible new methods for treating infertility. Nicholas Wade, writing in the New York Times, adds, "The ability to isolate stem cells from which eggs could be cultivated would help not only with fertility but also with biologists’ understanding of how drugs and nutrition affect the egg cells."

RELATED: Gecko Foot Glue; When Alcohol Is a Health Food

Jonathan Tilly, the director of Mass General's Vincent Center for Reproductive Biology and leader of the new research, had reported in 2004 that ovarian stem cells in mice could create new eggs "similar to how stem cells in male testes produce sperm throughout a man’s life." His new study attempted to prove this with humans. Researchers took healthy ovaries from patients having sex reassignment surgery, and injected stem cells from the ovaries into human ovarian tissue grafted under the skin of mice: "Within two weeks, early stage human follicles with oocytes had formed." Ryan Flinn writes in Bloomberg Businessweek that this could potentially point at "new ways to aid fertility by delaying when the ovaries stop functioning." 

RELATED: The Super Discriminating Powers of Ovulating Women

Dr. Tilly has long been a proponent of the belief that women might be able to produce new eggs, and has said the 50-year belief otherwise is based on lack of evidence rather than on data proving that it's impossible. In 2005, he reported that women have a "hidden reserve of cells in the bone marrow that constantly replenish the ovaries with new eggs," though other researchers have not been able to confirm his finding. 

RELATED: Richard Dawkins Gets into a Comments War with Feminists

Along with opening new doors to understanding the incredibly complex human egg cell, this new research could eventually have very practical implications for the 10 percent of child-bearing age women in the U.S. who have fertility problems. More philosophically, it opens up a new way of thinking about the hard-stop in women's lives for having kids. While fertility technologies like in-vitro and egg freezing are happening to some extent, Tilly's team is exploring the way this new knowledge could improve in-vitro -- IVF involves a limited number of eggs -- and also looking into possibility of developing an ovarian stem-cell bank with eggs that could be "cryogenically frozen and thawed without damage, unlike human eggs." 

“The problem we face with IVF is we don’t have many eggs to work with,” said Tilly. “These cells are renewable. If we are successful -- and it’s a big if -- in generating functioning eggs from these cells, we can generate as many eggs as we need to on a per patient basis.”

Researchers warn that there's a ways to go before there are any real applications to this, if ever. Female reproduction expert David Albertini said it's still unclear whether the egg cells yielded actually could be used in human fertility. Cells grown in laboratories are more likely to develop abnormalities; even if they are proven viable, it's a given that there will be numerous social and political aspects that factor in down the road. Nonetheless, evidence that women's eggs may not be the finite commodity we all thought they were seems poised to make a huge impact across many aspects of contemporary life. What would if mean, for instance, if the old ticking "biological clock" no longer applied -- or applied to women and men more equivalently? 

RELATED: Your Daughter's Science Role Model: A Cartoon Space Chimp

As Tilly said in a recording released to the press, "If we can guide the process correctly, I think it opens up a chance that sometime in the future, we might get to the point of actually having an unlimited source of human eggs. A woman could come in, have a small biopsy taken from her ovary for us to retrieve these cells. Once we get these cells out, we can take a hundred of them and make a million of them. If we can get to the stage of generating functional human eggs outside the body, it would rewrite essentially human assisted reproduction."

RELATED: Lubrication Can Be Good, Caffeine Can Be Bad

Brave new world? Maternity ages stretching into the 50s and 60s? Or simply another step toward the prediction some have made that sex will be just a recreational activity in another 10 years?

Go here to see the original:
New Stem Cell Research Could End the Hard Stop of Female Fertility